- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Mediators of Inflammation
Volume 2014 (2014), Article ID 858763, 7 pages
Toll-Like Receptor 4 in Bone Marrow-Derived Cells Contributes to the Progression of Diabetic Retinopathy
1The Department of Medical Genetics, Tongji Medical College Affiliated with Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan, Hubei 430022, China
2Radiology Department, Union Hospital Affiliated with Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, Hubei 430022, China
3The Department of Ophthalmology, Union Hospital Affiliated with Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, Hubei 430022, China
4The Department of Ophthalmology, No. 1 Hospital of Xian City, 30 Powder Lane, South Street, Xi’an, Shanxi 710002, China
5Department of Surgery, University of Pittsburgh Medical Center, NW607 MUH, 3459 Fifth Avenue, Pittsburgh, PA 25213, USA
6The Department of Emergency Surgery, Union Hospital Affiliated with Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, Hubei 430022, China
Received 11 February 2014; Revised 25 June 2014; Accepted 24 July 2014; Published 17 August 2014
Academic Editor: Eeva Moilanen
Copyright © 2014 Hui Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Diabetic retinopathy (DR) is a major microvascular complication in diabetics, and its mechanism is not fully understood. Toll-like receptor 4 (TLR4) plays a pivotal role in the maintenance of the inflammatory state during DR, and the deletion of TLR4 eventually alleviates the diabetic inflammatory state. To further elucidate the mechanism of DR, we used bone marrow transplantation to establish reciprocal chimeric animals of TLR4 mutant mice and TLR4 WT mice combined with diabetes mellitus (DM) induction by streptozotocin (STZ) treatment to identify the role of TLR4 in different cell types in the development of the proinflammatory state during DR. TLR4 mutation did not block the occurrence of high blood glucose after STZ injection compared with WT mice but did alleviate the progression of DR and alter the expression of the small vessel proliferation-related genes, vascular endothelial growth factor (VEGF), and hypoxia inducible factor-1α (HIF-1α). Grafting bone marrow-derived cells from TLR4 WT mice into TLR4 mutant mice increased the levels of TNF-α, IL-1β, and MIP-2 and increased the damage to the retina. Similarly, VEGF and HIF-1α expression were restored by the bone marrow transplantation. These findings identify an essential role for TLR4 in bone marrow-derived cells contributing to the progression of DR.
Diabetic retinopathy (DR) is one of the most common microangiopathic complications of patients with diabetes mellitus (DM) . DR is an ocular manifestation of DM, affecting up to 80% of all patients who have had DM for 10 years or more.
The mechanism of DR is far from fully understood. Several studies have suggested that low-grade inflammation is an important characteristic of DR . Its core pathological process is elicited by inflammatory injury to the vascular endothelial cells in the retina, which is followed by the angiogenesis of small vessels in the early stage [3–5].
Toll-like receptors (TLRs) belong to a family of transmembrane receptors involved in damage-associated molecular pattern-induced immune activation. One of the most documented types of TLR is toll-like receptor 4 (TLR4), which is expressed on various cell types [6, 7]. Previous studies implicated TLR4 in the regulation of a variety of inflammatory or immune-related disorders [8–11].
Recent findings have demonstrated that TLR4 polymorphisms are associated with the inflammatory state during DM and with complications including DR [12–15]. TLR4 has been shown to play an important role in DR. Thus, therapies directed at inhibiting TLR4 could be an alternative method to alleviate DR. How can these findings be used to improve the current DR treatment? Will such therapies be bone marrow directed? To further elucidate the function of TLR4 during DR, we performed bone marrow transplantation to create reciprocal chimeric TLR4 KO and TLR4 WT mice and then established the diabetic retina mouse model using STZ treatment. The findings will deepen the knowledge about the mechanism of DR and also provide novel strategies to treat DR.
2. Materials and Methods
2.1. Mice and Reagents
Ten-week-old male C3H/HeN mice (Animal Center affiliated with Wuhan University) and C3H/HeJ mice (Animal Center of the Military Medicine Science Institute) with bodyweights between 18 and 25 grams were housed in an SPF environment under a 12 hr light and 12 hr dark cycle. All animal protocols were approved by the Animal Care and Use Committee of the Huazhong University of Science and Technology (HUST). The 60Coγ radiation therapy instrument was provided by the cancer center of Wuhan Union Hospital. The STZ solution was purchased from Peking. The One-Touch Ultra automatic blood glucose monitoring system was obtained from Johnson Medical Instrument Limited (China). TNF-α, IL-1β, and MIP-2 ELISA kits and the ICAM-1 antibody were purchased from R&D Systems (USA), and the primers for the amplification of the VEGF and HIF1-α genes were purchased from Qiagen (USA). The type LZL-1 2 surgical microscope was from Zhenjiang (China), and the FEI Tecnai G12 electron microscope was from Tecnai (The Netherlands).
2.2. Bone Marrow Transplantation and Establishment of the Diabetes Mellitus Model
Chimeric mice were produced by transferring donor bone marrow cells into irradiated recipient animals using combinations of TLR4 wild type (WT) and mutant type (Mut) mice in the following donor/recipient groups: WT/WT, WT/Mut, Mut/Mut, and Mut/WT (Figure 1). Each recipient mouse was exposed to a one-time lethal exposure of 1000 cGy 60Coγ at a dosage of 100 cGy/min for ten min at 6 h before receiving 0.5–1 × 106 bone marrow cells via the tail vein. The bone marrow cells were prepared from the tibia and femur bones of the donor mice under sterile conditions. The tibias and femurs were excised and bisected under sterile conditions. The bone marrow was flushed using RPMI medium 1640 plus 5% calf serum. The marrow cells were collected, and red blood cells were lysed. Then, the cells were adjusted to a final concentration of 107 cells/mL and each mice was injected with 0.1 mL. Eight weeks after the bone marrow cell transfer, peripheral blood samples were obtained to verify the success of the engraftment. Then, these chimeric mice were injected with STZ (200 mg/kg, i.p., one dose) to induce DM. Blood glucose levels were monitored 72 hrs after the injection. Mice with blood glucose concentrations lower than 16.7 mmol/L received repeated doses of STZ (70 mg/kg, i.p.) until their blood glucose levels reached 16.7 mmol/L. Insulin was not administered to the mice during the course of the experiment to mimic a long natural history of DM and its associated microvascular complications. Samples were collected at 1, 2, and 4 months after the successful establishment of the DM model. Mice were divided into 4 DM groups: WT/WT (donor/recipient), WT/Mut, Mut/Mut, and Mut/WT. Each group contained 18 mice, and each time point had 6 mice from each group. In total, 72 chimeric mice were used (shown in Figure 1).
2.3. The Cytokine Levels in the Retina
Supernatants from homogenized retinal tissues were collected to determine the TNF-α, IL-1β, and MIP-2 levels. ELISA assays were conducted according to the manufacturer’s instructions and measured at 450 nm in a Bio-Rad ELISA reader. The results were analyzed using Bio-Linx Software (Bio-Rad, USA).
2.4. Retinal Expression of VEGF, HIF1-α mRNA
Total RNA was isolated from 0.1 mg of tissue using Trizol reagent (Gibco) following the manufacturer’s protocol. One-step reverse transcription polymerase chain reaction (RT-PCR) with real-time detection was performed using the QuantiTect SYBR Green RT-PCR Kit (Qiagen) on the BIO-RAD CFX96 real-time amplification system (USA) according to the manufacturer’s instructions. Cytokine expression was detected using a commercial Quantitec Primer Assay (Qiagen).
2.5. Electron Microscope Imaging of the Retina
After anesthetization using pentobarbital, the eyes were harvested, placed on ice, and fixed with Karnovsky’s solution for transmission electron microscope observation. The tissues were cut into small pieces, stored in 2% glutaraldehyde, fixed with osmium tetroxide, and embedded in an Epon 812 mixture. Samples were sectioned using an ultramicrotome, stained with uranyl acetate and lead citrate, and examined under an FEI Tecnai G2 electron microscope (FEI, Eindhoven, The Netherlands).
The data are expressed as the means ± SE. Differences between any two groups were determined by the t-test. Differences among multiple groups were determined by one-way ANOVA test. was considered statistically significant (SPSS10.0 software, Public Hygiene and Health Academy in Tongji Medical College Affiliated with Huazhong University of Science and Technology).
3. Results and Discussion
3.1. Blood Glucose Levels and Mortality after the Induction of Diabetes Mellitus
After bone marrow transplantation, all mice were housed under SPF conditions in the Animal Center of Tongji Medical College, HUST. All mice survived for 8 weeks. Then, the murine DM model was successfully induced by STZ injection. The blood glucose levels fluctuated between 16.6 mmol/L and 33.1 mmol/L, with an average level of 24.8 mmol/L. One month after the STZ injection, the mortality of the DM mice was 0 and increased to 4.17% at the end of 2 months [1 mouse in the Mut/Mut group died at 22 weeks (1/24)] after injection. The mortality reached 29.17% after 4 months [1 mouse in the WT/WT group died at 31 weeks and 2 mice in each of the other 3 groups died during the last week (7/24)] without the subcutaneous injection of insulin to control the blood glucose levels. After the STZ injection, the mice exhibited typical DM symptoms, such as polyuria, polydipsia, polyphagia, and marasmus. No difference in the blood glucose level was found among the groups of mice.
3.2. TLR4 in Bone Marrow-Derived Cells Plays a Key Role in the Angiogenesis of the Retina, as Visualized by Transmission Electron Microscopy
Morphological changes in the precapillary arterioles, capillaries, and venules with diameters less than 100 μm were detected before injuries to the visual field or fundus became visible by ophthalmoscopic examination or fluorescein angiography. Using transmission electron microscopy, we examined the retinal ultrastructure of the mice at the end of 4 months after the STZ injection. In the WT/WT mice, thickening of the basal membrane of small vessels with or without narrowing or closure of the lumen was observed (Figure 2(a)). The nuclear membrane structure was not integrated, and the intranuclear gap was wider. In some fields, massive swelling in the mitochondria or pericytes was observed (Figure 2(a) inset). Multifoci-responsive microvilli pointing to the lumen were observed in the endothelial cells, which is rather specific to DR. Compared with the WT/WT mice, the Mut/Mut mice showed much milder changes (Figure 2(d)). Reconstruction of the irradiated WT mice with TLR4 mutant bone marrow cells (the Mut/WT group) significantly reversed the pathological changes observed in the WT/WT mice (Figure 2(b)). These results strongly suggest that TLR4 in bone marrow-derived cells indeed contributes to the progression of DR.
3.3. Transplantation of TLR4 WT Bone Marrow-Derived Cells into Mutant Mice Restores Cytokine Release into the Retina
The underlying mechanism of the DR pathogenesis still remains unknown given that DR results from multifactorial and complicated crosstalk among many factors. Even as early as 2001, the pathological basis of DR was noted to be a type of subacute or chronic inflammatory response . To investigate the retinal inflammatory state, we measured the expression of some typical inflammatory mediators: TNF-α, IL-1β, and MIP-2. As shown in Figure 3, the levels of these inflammatory mediators were much higher in the WT/WT mice than in the Mut/Mut mice (◆), which is somewhat consistent with a previous study . However, after engraftment of the irradiated TLR4 mutant mice with bone marrow-derived TLR4 WT cells in the WT/Mut group, we restored the released cytokines in these mutant mice almost to the levels observed in the WT/WT mice (▲). However, the cytokine release decreased dramatically when the irradiated WT mice received grafts with the bone marrow cells from TLR4 mutant mice in the Mut/WT group (★, #).
Early changes in the retinal MIP-2 levels are similar to those of TNF-α and IL-1β. However, during the later stages (4 months after the induction of DM), no difference in the MIP-2 levels was observed among the 4 groups (, ANOVA). One possible explanation is that MIP-2 exerts its function mainly in the early stage to recruit inflammatory cells to the highly inflamed retina (Figure 1(a) inset). During the later stage, MIP-2 function may be partially replaced by TNF-α because this cytokine also has chemotactic effects and could drive DR progression. Throughout DR progression, the TNF-α levels remained very high. These results indicated that bone marrow-derived TLR4 controls the initiation and progression of DR. This result agrees with other studies demonstrating that TLR4 in bone marrow-derived cells plays vital roles in the release of cytokines under many sterile inflammatory conditions [18–22].
However, other reports indicate that TLR4 in both bone marrow-derived and parenchymal cells could be involved in such inflammatory conditions. Delineating the roles of TLR4 from different cell origins is very complicated [22, 23].
3.4. Transplantation of TLR4 WT Bone Marrow-Derived Cells into Mutant Mice Restored the Expression of Genes Related to the Angiogenesis of Small Vessels
Vascular endothelial growth factor (VEGF) is the most potent factor for stimulating physiological and pathological angiogenesis. The key pathological change, namely, retinal neovascularization, is associated with DM progression and is regulated by VEGF and hypoxia inducible factor-1α (HIF-1α) [24, 25]. Because the angiogenesis of small vessels is widely associated with the progression of DM, the ongoing retinopathy, and the obvious deoxygenation due to the malformation of the new vasculature, we chose to measure the VEGF and HIF-1α levels in the retinal tissue . Because the VEGF and HIF-1α levels in a single mouse retina are too low to be detected by western blot or ELISA (data not shown), we used real-time quantitative PCR to detect the changes in the VEGF and HIF-1α mRNA levels. Our results indicate that the expression of both genes is much higher in the WT/WT mice than in the Mut/Mut group (Figure 4: ◆). Grafting bone marrow-derived cells from WT mice into irradiated TLR4 mutant mice in the WT/Mut group restored the expression of these two genes (▲). Grafting bone marrow-derived cells from TLR4 mutant mice into irradiated TLR4 WT mice in the Mut/WT group failed to increase the expression of these two genes (★). These results suggest that TLR4 in bone marrow-derived cells is crucial for retinal neovascularization during DR. However, DM alone is known to hinder the mobilization of cells from the bone marrow as monocytes or PMN . How should this issue be clearly addressed? There are still many questions to be answered especially under some persistent inflammatory state as DR.
In summary, the present study demonstrated for the first time that TLR4 in bone marrow-derived cells plays essential roles in the progression of DR and can be targeted for the prevention or treatment of DR. However, the present study focused only on TLR4 in bone marrow-derived cells during DR pathogenesis . We cannot exclude the contribution of TLR4 in other cell types, such as retinal pigment epithelial cells, mononuclear cells, and gliocytes, to the development of DR . Some of these cell types could also elicit very powerful immune responses, such as cytokine release . Even in the retina, two distinct populations of myeloid-derived cells exist: perivascular cells (PVCs) and microglia (MG) . The crosstalk between TLR4 in these cells and other immune effectors/immunomodulators remains unconfirmed and needs to be further explored.
|TLR4:||Toll-like receptor 4|
|TNF-α:||Tumor necrosis factor-alpha|
|MIP-2:||Macrophage inflammatory protein 2|
|VEGF:||Vascular endothelial growth factor|
|HIF-1α:||Hypoxia inducible factor-1 alpha|
Conflict of Interests
No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this paper.
This work was supported by the National Natural Science Foundation of China (Grants nos. 30801266 and 81070355). The authors thank the technicians in the Cancer Center of Union Hospital, HUST, for their valuable assistance.
- A. W. Stitt, N. Lois, R. J. Medina, P. Adamson, and T. M. Curtis, “Advances in our understanding of diabetic retinopathy,” Clinical Science, vol. 125, no. 1, pp. 1–17, 2013.
- D. A. Antonetti, A. J. Barber, S. K. Bronson et al., “Diabetic retinopathy: seeing beyond glucose-induced microvascular disease,” Diabetes, vol. 55, no. 9, pp. 2401–2411, 2006.
- Y. Liu, L. F. Leo, C. McGregor, A. Grivitishvili, C. J. Barnstable, and J. Tombran-Tink, “Pigment epithelium-derived factor (PEDF) peptide eye drops reduce inflammation, cell death and vascular leakage in diabetic retinopathy in Ins2(Akita) mice,” Molecular Medicine, vol. 18, pp. 1387–1401, 2012.
- M. Roh, Y. Zhang, Y. Murakami, et al., “Etanercept, a widely used inhibitor of tumor necrosis factor-α (TNF-α), prevents retinal ganglion cell loss in a rat model of glaucoma,” PLoS One, vol. 7, no. 7, Article ID e40065, 2012.
- C. M. McVicar, R. Hamilton, L. M. Colhoun et al., “Intervention with an erythropoietin-derived peptide protects against neuroglial and vascular degeneration during diabetic retinopathy,” Diabetes, vol. 60, no. 11, pp. 2995–3005, 2011.
- S. G. Elner, H. R. Petty, V. M. Elner et al., “TLR4 mediates human retinal pigment epithelial endotoxin binding and cytokine expression,” Investigative Ophthalmology and Visual Science, vol. 46, no. 12, pp. 4627–4633, 2005.
- H. S. Lee, T. Hattori, E. Y. Park, W. Stevenson, S. K. Chauhan, and R. Dana, “Expression of toll-like receptor 4 contributes to corneal inflammation in experimental dry eye disease,” Investigative Ophthalmology and Visual Science, vol. 53, no. 9, pp. 5632–5640, 2012.
- D. F. Ben, X. Y. Yu, G. Y. Ji et al., “TLR4 mediates lung injury and inflammation in intestinal ischemia-reperfusion,” Journal of Surgical Research, vol. 174, no. 2, pp. 326–333, 2012.
- B. Z. Zhang, G. Ramesh, S. Uematsu, S. Akira, and W. B. Reeves, “TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity,” Journal of the American Society of Nephrology, vol. 19, no. 5, pp. 923–932, 2008.
- H. Tang, S. Pang, M. Wang et al., “TLR4 activation is required for IL-17-induced multiple tissue inflammation and wasting in mice,” The Journal of Immunology, vol. 185, no. 4, pp. 2563–2569, 2010.
- V. O. Millien, W. Lu, J. Shaw et al., “Cleavage of fibrinogen by proteinases elicits allergic responses through toll-like receptor 4,” Science, vol. 341, no. 6147, pp. 792–796, 2013.
- M. Buraczynska, I. Baranowicz-Gaszczyk, J. Tarach, and A. Ksiazek, “Toll-like receptor 4 gene polymorphism and early onset of diabetic retinopathy in patients with type 2 diabetes,” Human Immunology, vol. 70, no. 2, pp. 121–124, 2009.
- P. Liu, F. Li, M. Qiu, et al., “Expression and cellular distribution of TLR4, MyD88, and NF-B in diabetic renal tubulointerstitial fibrosis, in vitro and in vivo,” Diabetes Research and Clinical Practice, 2014.
- K. Singh, S. Kant, V. K. Singh, et al., “Toll-like receptor 4 polymorphisms and their haplotypes modulate the risk of developing diabetic retinopathy in type 2 diabetes patients,” Molecular Vision, vol. 20, pp. 704–713, 2014.
- E. M. Kawamoto, R. G. Cutler, S. M. Rothman, et al., “TLR4-dependent metabolic changes are associated with cognitive impairment in an animal model of type 1 diabetes,” Biochemical and Biophysical Research Communications, vol. 443, no. 2, pp. 731–737, 2014.
- L. Huang, W. Xu, and G. Xu, “Transplantation of CX3CL1-expressing mesenchymal stem cells provides neuroprotective and immunomodulatory effects in a rat model of retinal degeneration,” Ocular Immunology and Inflammation, vol. 21, no. 4, pp. 276–285, 2013.
- S. Devaraj, P. Tobias, and I. Jialal, “Knockout of toll-like receptor-4 attenuates the pro-inflammatory state of diabetes,” Cytokine, vol. 55, no. 3, pp. 441–445, 2011.
- A. Tsung, R. A. Hoffman, K. Izuishi et al., “Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in nonparenchymal cells,” The Journal of Immunology, vol. 175, no. 11, pp. 7661–7668, 2005.
- J. E. Juskewitch, J. L. Platt, B. E. Knudsen, K. L. Knutson, G. J. Brunn, and J. P. Grande, “Disparate roles of marrow-and parenchymal cell-derived TLR4 signaling in murine LPS-induced systemic inflammation,” Scientific Reports, vol. 2, article 918, pp. 1–10, 2012.
- M. A. Schmid, H. Takizawa, D. R. Baumjohann, Y. Saito, and M. G. Manz, “Bone marrow dendritic cell progenitors sense pathogens via Toll-like receptors and subsequently migrate to inflamed lymph nodes,” Blood, vol. 118, no. 18, pp. 4829–4840, 2011.
- S. Inokuchi, H. Tsukamoto, E. Park, Z. Liu, D. A. Brenner, and E. Seki, “Toll-like receptor 4 mediates alcohol-induced steatohepatitis through bone marrow-derived and endogenous liver cells in mice,” Alcoholism: Clinical and Experimental Research, vol. 35, no. 8, pp. 1509–1518, 2011.
- K. P. Mollen, R. M. Levy, J. M. Prince et al., “Systemic inflammation and end organ damage following trauma involves functional TLR4 signaling in both bone marrow-derived cells and parenchymal cells,” Journal of Leukocyte Biology, vol. 83, no. 1, pp. 80–88, 2008.
- W. Hui, Z. Jinxiang, W. Heshui, L. Zhuoya, and Z. Qichang, “Bone marrow and non-bone marrow TLR4 regulates hepatic ischemia/reperfusion injury,” Biochemical and Biophysical Research Communications, vol. 389, no. 2, pp. 328–332, 2009.
- C. Li, P. Chen, J. Zhang et al., “Enzyme-induced vitreolysis can alleviate the progression of diabetic retinopathy through the HIF-1α pathway,” Investigative Ophthalmology & Visual Science, vol. 54, no. 7, pp. 4964–4970, 2013.
- R. A. Feit-Leichman, R. Kinouchi, M. Takeda et al., “Vascular damage in a mouse model of diabetic retinopathy: relation to neuronal and glial changes,” Investigative Ophthalmology and Visual Science, vol. 46, no. 11, pp. 4281–4287, 2005.
- J. Liu, D. A. Copland, S. Horie et al., “Myeloid cells expressing VEGF and arginase-1 following uptake of damaged retinal pigment epithelium suggests potential mechanism that drives the onset of choroidal angiogenesis in mice,” PLoS ONE, vol. 8, no. 8, Article ID e72935, 2013.
- G. Li, A. A. Veenstra, R. R. Talahalli et al., “Marrow-derived cells regulate the development of early diabetic retinopathy and tactile allodynia in mice,” Diabetes, vol. 61, no. 12, pp. 3294–3303, 2012.
- S. Nakamura, S. Imai, H. Ogishima, K. Tsuruma, M. Shimazawa, and H. Hara, “Morphological and functional changes in the retina after chronic oxygen-induced retinopathy,” PLoS ONE, vol. 7, no. 1, Article ID e32167, 2012.
- H. Kohno, Y. Chen, B. M. Kevany et al., “Photoreceptor proteins initiate microglial activation via toll-like receptor 4 in retinal degeneration mediated by all-trans-retinal,” The Journal of Biological Chemistry, vol. 288, no. 21, pp. 15326–15341, 2013.
- R. T. Liu, J. Gao, S. Cao et al., “Inflammatory mediators induced by amyloid-beta in the retina and RPE in vivo: implications for inflammasome activation in age-related macular degeneration,” Investigative Ophthalmology and Visual Science, vol. 54, no. 3, pp. 2225–2237, 2013.
- H. Kaneko, K. M. Nishiguchi, M. Nakamura, S. Kachi, and H. Terasaki, “Characteristics of bone marrow-derived microglia in the normal and injured retina,” Investigative Ophthalmology and Visual Science, vol. 49, no. 9, pp. 4162–4168, 2008.